Categories
| Category | |
|---|---|
| Pharmacy | 60% |
| Health Conditions and Concerns | 20% |
| Medicine | 10% |
| Others | 10% |
Explore sites in same category:
- qelbree.com Rank 1.2M. Estimated value 1,800$
- muramed.com Rank 2M. Estimated value 1,080$
- sunovionprofile.com Rank 1.4M. Estimated value 1,500$
- pillsync.com Rank 1.3M. Estimated value 1,620$
- rocketrx.com Rank 759K. Estimated value 2,844$
- mounjaro.com Rank 153.7K. Estimated value 14,208$
- paxlovid.com Rank 139.7K. Estimated value 15,648$
- jsnp.org Rank 2.7M. Estimated value 792$
- dpdcir.com Rank 181.5K. Estimated value 12,012$
- rapidtestandtrace.ca Rank 2.2M. Estimated value 996$
Keyword Suggestion
Domain Informations
Xolair.com lookup results from whois.markmonitor.com server:
- Domain created: 1999-12-08T07:47:13Z
- Domain updated: 2023-11-06T09:06:03Z
- Domain expires: 2025-12-08T07:47:13Z 0 Years, 231 Days left
- Website age: 25 Years, 134 Days
- Registrar Domain ID: 14823155_DOMAIN_COM-VRSN
- Registrar Url: http://www.markmonitor.com
- Registrar WHOIS Server: whois.markmonitor.com
- Registrar Abuse Contact Email: [email protected]
- Registrar Abuse Contact Phone: +1.2086851750
- Name server:
- A1-254.AKAM.NET
- A2-66.AKAM.NET
- A24-65.AKAM.NET
- A28-67.AKAM.NET
- A7-64.AKAM.NET
- A9-65.AKAM.NET
- DNS1.NOVARTIS.COM
- DNS2.NOVARTIS.COM
- DNS3.NOVARTIS.COM
- DNS4.NOVARTIS.COM
Network
- inetnum : 54.193.0.0 - 54.193.255.255
- name : AMAZO-ZSFO4
- handle : NET-54-193-0-0-1
- status : Reallocated
- created : 2011-08-11
- changed : 2021-07-22
- desc : The activity you have detected originates from a dynamic hosting environment.,For fastest response, please submit abuse reports at http://aws-portal.amazon.com/gp/aws/html-forms-controller/contactus/AWSAbuse,For more information regarding EC2 see:,http://ec2.amazonaws.com/,All reports MUST include:,* src IP,* dest IP (your IP),* dest port,* Accurate date/timestamp and timezone of activity,* Intensity/frequency (short log extracts),* Your contact details (phone and email) Without these we will be unable to identify the correct owner of the IP address at that point in time.
Owner
- organization : Amazon.com, Inc.
- handle : AMAZO-48
- address : Array,Seattle,WA,98144,US
Technical support
- handle : ANO24-ARIN
- name : Amazon EC2 Network Operations
- phone : +1-206-555-0000
- email : [email protected]
Abuse
- handle : AEA8-ARIN
- name : Amazon EC2 Abuse
- phone : +1-206-555-0000
- email : [email protected]
| Domain Provider | Number Of Domains |
|---|---|
| godaddy.com | 286730 |
| namecheap.com | 101387 |
| networksolutions.com | 69118 |
| tucows.com | 52617 |
| publicdomainregistry.com | 39120 |
| whois.godaddy.com | 32793 |
| enomdomains.com | 23825 |
| namesilo.com | 21429 |
| domains.google.com | 21384 |
| cloudflare.com | 20573 |
| gmo.jp | 18110 |
| name.com | 17601 |
| fastdomain.com | 14708 |
| register.com | 13495 |
| net.cn | 12481 |
| ionos.com | 12416 |
| ovh.com | 12416 |
| gandi.net | 12305 |
| registrar.amazon.com | 12111 |
Host Informations
- IP address: 54.193.66.173
- Location: San Jose United States
- Latitude: 37.3388
- Longitude: -121.8914
- Timezone: America/Los_Angeles
Site Inspections
Port Scanner (IP: 54.193.66.173)
Spam Check (IP: 54.193.66.173)
Websites Listing
We found Websites Listing below when search with xolair.com on Search Engine
Contact Us - XOLAIR® (omalizumab)
2018-01-15 · A 5-year observational study was conducted in 5007 XOLAIR-treated and 2829 non-XOLAIR-treated patients ≥12 years of age with moderate to severe persistent asthma and a positive skin test reaction to a perennial aeroallergen to evaluate the long term safety of XOLAIR, including the risk of malignancy. Similar percentages of patients in both cohorts were current …
Xolairhcp.comPrivacy Policy | XOLAIR® (omalizumab)
E-mail Content to a Friend. Information obtained from you regarding friend or family name and e-mail address, if you elect to use our referral service for sending some of our website content to friends and family. We may use this personally identifiable information to automatically send the friend or family member a one-time e-mail inviting them to visit the website. We may store this ...
Xolair.comXOLAIR® (Omalizumab) for Allergic Asthma, Nasal Polyps ...
XOLAIR is not used to treat other allergic conditions or sudden breathing problems. Chronic idiopathic urticaria (CIU, chronic hives without a known cause) in people 12 years of age and older who continue to have hives that are not controlled with H1 antihistamine treatment. It is not known if XOLAIR is safe and effective in people with CIU under 12 years of age. XOLAIR is …
Xolair.comChronic Spontaneous Urticaria Treatment - XOLAIR
The most common side effects of XOLAIR in people with chronic spontaneous urticaria: nausea, headaches, swelling of the inside of your nose, throat or sinuses, cough, joint pain, and upper respiratory tract infection. These are not all the possible side effects of XOLAIR. Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA …
Xolair.comXolair ® CSU
† Xolair® 300 mg vs. baseline at 12 weeks; p<0.001 vs. placebo. ‡ Xolair® is also available as a lyophilized formulation. References: 1. Maurer M, et al. N Engl J Med 2013;368:924-935. 2. Weller K, et al. J Eur Acad Dermatol Venereol 2013;27:43-50. 3. Maurer M, et al. N Engl J Med 2013;368:924-935. 4. Zuberbier T, et al. Allergy 2014;69:868-887. 5. Xolair® Summary of …
Xolaircsu.comXOLAIR - Patient Saving Program
XOLAIR - Patient Saving Program
Xolaircopay.comSelf-Injection | XOLAIR® (omalizumab)
Before receiving XOLAIR, tell your healthcare provider about all of your medical conditions, including if you: have a latex allergy or any other allergies (such as food allergy or seasonal allergies). The needle cap on the XOLAIR prefilled syringe contains a type of natural rubber latex. have sudden breathing problems (bronchospasm) have ever had a severe allergic reaction …
Xolair.comXolair (omalizumab) | Asthma.net
2016-03-05 · Xolair (omalizumab) is an anti-IgE antibody. Xolair is approved to treat people ages 6 years and up with moderate to severe persistent asthma and a proven allergy to a year-round allergen. 1 You should have a skin or blood allergy test to confirm your allergies. Xolair is intended to treat people whose asthma is not controlled with inhaled corticosteroids.
Asthma.netOmalizumab (Xolair) - IVX Health
Rev. 10/5/2021 OMALIZUMAB (XOLAIR) ORDERS page 1 of 2 Email [email protected] or fax this form, insurance card (both sides), demographics, recent H&P, labs, and supporting clinicals to: BAY AREA: 844-889-0275 CINCINNATI: 844-9 46-0868 CHICAGO: 312-253-7244 COLUMBUS: 844-627-2675 HARRISBURG: 844-859-4235 INDIANAPOLIS: 844- 983-2028 …
Ivxhealth.comPATIENT INFORMATION LETTER: XOLAIR (OMALIZUMAB) What is ...
Xolair in 3 (< 0.1%) study volunteers without other identifiable allergic triggers. These events included hives and throat and/or tongue swelling. At the first sign of a generalized allergic reaction, adrenaline (epinephrine) is usually given to counteract the reaction. Severe reactions that include chest symptoms are treated in the same way that an asthma attack would be …
Hopkinsmedicine.orgXOLAIR® (omalizumab) Home - Novartis UK HCP Portal
Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV 1 <80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented ...
Health.novartis.co.ukXOLAIR® Omalizumab For Subcutaneous Use DESCRIPTION
XOLAIR® Omalizumab For Subcutaneous Use DESCRIPTION Xolair (Omalizumab) is a recombinant DNA-derived humanized IgG1κ monoclonal antibody that selectively binds to human immunoglobulin E (IgE). The antibody has a molecular weight of approximately 149 kilodaltons. Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium …
Accessdata.fda.govXOLAIR Omalizumab 1. PRODUCT NAME - Medsafe
Xolair must not be administered by the intravenous or intramuscular route. Doses of more than 150 mg should be divided across two or more injection sites. There is limited experience with self-administration of Xolair powder and solvent for solution for injection. Therefore treatment with this formulation is intended to be administered by a healthcare professional only. Full instructions …
Medsafe.govt.nzXOLAIR - PLM
En un estudio Fase IV de observación subsecuente donde se compararon 5,007 pacientes tratados con XOLAIR ® y 2,829 que no fueron tratados con XOLAIR ® a los cuales se les dio seguimiento durante un máximo de 5 años, las tasas de incidencia de tumores malignos primarios por cada 1,000 pacientes-año fueron 16.01 para el grupo con XOLAIR ® …
Medicamentosplm.comKris Aquino Health Update After Receiving Xolair Injection
2022-03-02 · As she did the treatment, her two sons were also beside her. She then added, “Thank you for your prayers- supposed to rest this week, then March 13 ang next shot- then after 5 days, praying nothing goes wrong, we finally go abroad & i continue my next doses of Xolair and finally tackle my autoimmune and other important health problems. In case magtatanong …
Philnews.phXolair Information, Side Effects, Warnings and Recalls
Get email alerts and dashboard notifications when your medications are recalled by the FDA. *. * * * * Or login with: ... Xolair is a sterile, white, preservative free, lyophilized powder contained in a single use vial that is reconstituted with Sterile Water for Injection (SWFI), USP, and administered as a subcutaneous (SC) injection. Each 202.5 mg vial of omalizumab also contains L-histidine ...
Recallguide.orgAlvotech Enters Exclusive Global Licensing Agreement with ...
2022-02-02 · AVT23 is a proposed biosimilar to Xolair (omalizumab). Omalizumab is an antibody that targets free IgE; it is used to improve the control of severe persistent allergic asthma, for chronic (long-term) spontaneous urticaria (itchy rash) in patients with elevated IgE who do not respond to treatment with antihistamines and to treat nasal polyps in people 18 …
Financialpost.comInvestigation Report on China's Omalizumab Markets, 2016 ...
2022-03-07 · DUBLIN, March 07, 2022--The "Investigation Report on China's Omalizumab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
Finance.yahoo.comXolair (Omalizumab) - Angioedema News
Xolair (omalizumab) is a prescription medication developed by Novartis and approved for the treatment of allergic asthma and chronic idiopathic urticaria.The therapy is also being investigated for the treatment of angioedema, a skin reaction characterized by frequent swelling of the deeper layer of the skin and mucous membranes.Episodes of angioedema are common in chronic …
Angioedemanews.comAlvotech In-Licenses Xolair Rival From BiosanaPharma ...
2022-02-02 · Alvotech has delivered on indications that it would look to collaborate on certain biosimilar opportunities in future, striking a licensing deal with BiosanaPharma that will see the two firms partner to co-develop an omalizumab biosimilar rival to Xolair.
Generics.pharmaintelligence.informa.com
Domains Expiration Date Updated
| Site | Provider | Expiration Date |
|---|---|---|
| noblehomesjacksonville.com | godaddy.com | -2 Years, -302 Days |
| maphilo.net | networksolutions.com | 1 Year, 283 Days |
| ecomobl.com | godaddy.com | -2 Years, -213 Days |
| flpirq.com | directnic.com | -2 Years, -145 Days |
| morelaw.com | namecheap.com | -2 Years, -108 Days |
| squper.com | reg.ru | -2 Years, -250 Days |
| theminimilitia.com | namecheap.com | -2 Years, -160 Days |
| bonjoursagan.com | gmo.jp | 1 Year, 320 Days |
| xsw5.com | godaddy.com | -2 Years, -304 Days |
| pxquest.com | registrar.amazon.com | -2 Years, -149 Days |